Brazil is the natural choice for venture-backed biosolutions seeking scale, but only the well-capitalised will survive.
Over the past year, a growing number of biosolutions companies from the US and Europe have arrived in Brazil. They are working across crop protection, soil health, livestock, biological measurement and renewable energy.
Brazil gives them plenty of reasons to come. It offers year-round biological pressure, several growing cycles, enormous farms and one of the world’s largest agricultural markets.
For venture-backed companies, there is another attraction. Brazil may be one of the few agricultural markets large enough to support the growth their investors expect.
For these companies, Brazil offers much more than a place to test a product. It has the scale to turn a promising technology into a venture-scale business.
Search for Scale
Biological products have attracted significant investment over the past decade, driven by the promise that crop protection, animal health and soil technologies can take market share from conventional chemistry as concerns around resistance, environmental impact and sustainability grow.
Commercial growth, however, has often proved slower than expected in Europe and North America. Farmers have short planting windows, regulation takes time and biological performance can vary under field conditions.
In Brazil, the market is already growing quickly. Sales of biological inputs surpassed US$1.2 billion in 2025, up 15% from the previous year. The total area treated with biological products, including repeat applications on the same land, grew by 28%.
This impressive growth has caught the attention of foreign biotech startups. US-based GreenLight Biosciences entered Brazil in 2025 with an RNA-based product designed to control agricultural pests.
The company later received US$25 million from climate investor Just Climate to support the commercialisation of its agricultural platform, with Brazil playing a central role in that expansion.
Ascribe Bioscience, a Yield Lab portfolio company, has also chosen Brazil as the first market for its crop protection technology. The US startup raised a US$12 million Series A backed by investors including Acre Venture Partners, Corteva and Syngenta Group Ventures.
Its lead product uses naturally occurring molecules from the soil microbiome to strengthen plants’ immune response. Starting in Brazil gives Ascribe access to major crops, high disease pressure and enough acreage to build meaningful revenue if the product performs.
Brazil’s potential extends well beyond crops. US animal-health biotech BiomEdit raised US$18.4 million in 2025 and acquired technology assets from UK-based Folium Science, including a platform for developing engineered biological products for livestock.
BiomEdit already has a poultry feed additive approved in Brazil and plans to launch two additional products in the country in 2027. Brazil’s position as the world’s largest exporter of chicken and beef gives animal-health companies access to production systems with genuine global scale.
Bioenergy provides another route to growth. Finnish biorefining company Chempolis is working with Brazil’s 4WOOD Biotech on a plant designed to turn bamboo into second-generation ethanol, lignin and other bioproducts.
The project is still moving through feasibility studies and discussions with investors. Its premise captures the Brazilian opportunity: abundant biomass, land suited to high-yield feedstocks and a domestic economy already comfortable with biofuels.
At the other end of the scale, Honeywell has been selected to provide ethanol-to-jet technology for a proposed Petrobras facility in São Paulo. The project could produce up to 10,000 barrels of sustainable aviation fuel per day, showing how biological feedstocks can support industrial opportunities far beyond the farm.
Built for Biology
Brazil’s tropical conditions create an unusually demanding environment for biological technologies. Heat, humidity, acidic soils and constant pressure from insects, fungi and nematodes provide plenty of opportunities to prove whether a product works.
Farmers can also plant two or even three crops in the same year. That gives companies more chances to run trials, improve formulations and generate data than they would get from a single annual growing season.
Scale shortens the journey from pilot to commercial deployment. A successful trial with one large producer, cooperative or agribusiness can open access to tens of thousands of hectares.
Brazil also has decades of experience using biology in agriculture. Inoculants are widely used in soybean production, biological pest control is well established and on-farm production has introduced many growers to microorganisms as agricultural tools.
The next challenge is precision, or, more specifically, bio-precision. Biological products need better information about what is happening in the soil, inside the plant and across large production systems.
US soil intelligence company EarthOptics has operated in Brazil since 2023 and says its technology has already been used across more than 600,000 hectares with around 700 producers. It combines sensors, soil sampling and data analysis to create detailed maps of soil conditions, which could make biological applications more targeted and their results easier to measure.
Dutch company Veridi is approaching the problem through diagnostics. It established a Brazilian operation in early 2026 and has developed a proprietary robotic microscope that scans soil samples and uses AI to identify nematode genera and species.
The system can process samples much faster and more consistently than the manual microscopy commonly used today. In Brazil, where nematodes are a major source of crop losses, faster identification could help farmers choose the right treatment before the damage spreads.
Established companies are reaching a similar conclusion. Rovensa Next has invested in local fermentation and research capacity, including a pilot plant in São Paulo that can help develop biological products for tropical agriculture and other global markets.
Tropical Trials
Brazil offers a large opportunity, although breaking into the market is rarely straightforward. The country is often treated as a single agricultural market, when in practice it is a collection of regions with different crops, climates, farm sizes, distribution systems and commercial relationships.
A product that performs well in the soybean fields of Mato Grosso may need a different formulation, application method or sales channel in Paraná. Results in sugarcane provide little indication of how easily the same company can move into coffee, citrus, vegetables or livestock.
Reaching farmers across such a diverse market requires the right local distribution strategy. Foreign companies can build their own commercial teams, work through established distributors or partner with a large agricultural input company, and each option involves different costs, margins and levels of control.
Building a local team takes time and significant capital, while distributors already manage crowded product portfolios. Larger partners can provide market access and credibility, although their commercial priorities may move more slowly than a venture-backed company needs.
Regulation and registration add another layer of cost and complexity. Data from Europe or the US may support the technical case for a product, but Brazilian farmers and regulators still expect evidence that it performs under local tropical conditions.
Price also matters in a market where farm budgets are under pressure from high interest rates, volatile commodity prices and expensive inputs. Farmers will try a new product when it solves an urgent problem and offers a clear return, while broader claims around sustainability or soil health may take several seasons to prove.
This extended path from field trial to repeat sales explains why capital is so important. Foreign companies need enough runway to remain in the market through several growing cycles while building local leadership, Portuguese-language support and relationships with farmers, cooperatives, researchers and distributors.
Those that make it through can build more than a Brazilian operation. They can develop products proven under some of the toughest agricultural conditions in the world, creating evidence and capabilities that can later support expansion into other tropical markets.
This is the real trial by tropics. Brazil offers the scale needed to build a venture-sized biosolutions business, while demanding the capital, patience and local knowledge required to reach it.
Thanks for reading.
KFG
Kieran Finbar Gartlan is an Irish native with more than 30 years’ experience living and working in Brazil. He is Managing Partner at The Yield Lab Latam, a leading venture capital firm investing in AgriFood and Climate Tech startups in Latin America.